{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:58:31Z","timestamp":1760241511415,"version":"build-2065373602"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"R\u00e9gion Hauts-de France and INSERM PhD Fellowship"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10637-025-01561-4","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T04:27:41Z","timestamp":1754281661000},"page":"844-856","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Direct functional HOXA9\/DNA-binding competitors versus epigenetic inhibitors of HOXA9 expression on cell proliferation, death and differentiation processes in the model of MLL-rearranged acute myeloid leukemia"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1720-8754","authenticated-orcid":false,"given":"Julie","family":"Vrevin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7472-4146","authenticated-orcid":false,"given":"M\u00e9lanie","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3326-5282","authenticated-orcid":false,"given":"Marine","family":"Andrique","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4598-6518","authenticated-orcid":false,"given":"Nathalie","family":"Jouy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9831-5577","authenticated-orcid":false,"given":"Marie-H\u00e9l\u00e8ne","family":"David-Cordonnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"1561_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74:203. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"key":"1561_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3322\/caac.21820","volume":"9","author":"B Liu","year":"2024","unstructured":"Liu B, Zhou H, Tan L, Siu KTH, Guan X-Y (2024) Exploring treatment options in cancer\u202f: tumor treatment strategies. Signal Transduct Target Ther 9:175. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"Signal Transduct Target Ther"},{"key":"1561_CR3","doi-asserted-by":"publisher","first-page":"13618","DOI":"10.3390\/ijms241713618","volume":"24","author":"HY Choi","year":"2023","unstructured":"Choi HY, Chang J (2023) Targeted therapy for cancers\u202f: from ongoing clinical trials to FDA approved drugs. Int J Mol Sci 24:13618. https:\/\/doi.org\/10.3390\/ijms241713618","journal-title":"Int J Mol Sci"},{"key":"1561_CR4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V108.11.734.734","volume":"108","author":"J Faber","year":"2006","unstructured":"Faber J et al (2006) HoxA9 knockdown inhibits proliferation and induces cell death in human MLL-rearranged leukemias. Blood 108:734. https:\/\/doi.org\/10.1182\/blood.V108.11.734.734","journal-title":"Blood"},{"key":"1561_CR5","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nrc2253","volume":"7","author":"AV Krivtsov","year":"2007","unstructured":"Krivtsov AV, Armstrong SA (2007) MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 7:823\u2013833. https:\/\/doi.org\/10.1038\/nrc2253","journal-title":"Nat Rev Cancer"},{"key":"1561_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1046\/j.1365-2141.2002.03803.x","volume":"119","author":"T Imamura","year":"2002","unstructured":"Imamura T, Morimoto A, Takanashi M, Hibi S, Sugimoto T (2002) Frequent co-expression of HoxA9 and Meis1 genes in infant acute lymphoblastic leukaemia with MLL rearrangement. Br J Haematol 119:119\u2013121. https:\/\/doi.org\/10.1046\/j.1365-2141.2002.03803.x","journal-title":"Br J Haematol"},{"key":"1561_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/sj.leu.2401410","volume":"13","author":"H Kawagoe","year":"1999","unstructured":"Kawagoe H, Humphries RK, Blair A, Sutherland HJ, Hogge DE (1999) Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells. Leukemia 13:687\u2013698. https:\/\/doi.org\/10.1038\/sj.leu.2401410","journal-title":"Leukemia"},{"key":"1561_CR8","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1126\/science.286.5439.531","volume":"286","author":"TR Golub","year":"1999","unstructured":"Golub TR et al (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286:531\u2013527. https:\/\/doi.org\/10.1126\/science.286.5439.531","journal-title":"Science"},{"key":"1561_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.2147\/OTT.S95279","volume":"9","author":"L Gao","year":"2016","unstructured":"Gao L, Sun J, Liu F, Zhang H, Ma Y (2016)) Higher expression levels of the HOXA9 gene, closely associated with MLL-PTD and EZH2 mutations, predict inferior outcome in acute myeloid leukemia. Onco Targets Ther 9:711\u2013722. https:\/\/doi.org\/10.2147\/OTT.S95279","journal-title":"Onco Targets Ther"},{"key":"1561_CR10","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/leu.2008.198","volume":"22","author":"M Andreeff","year":"2008","unstructured":"Andreeff M et al (2008) HOX expression patterns identify a common signature for favorable AML. Leukemia 22:2041\u20132047. https:\/\/doi.org\/10.1038\/leu.2008.198","journal-title":"Leukemia"},{"key":"1561_CR11","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3390\/cancers11060837","volume":"17","author":"M Lambert","year":"2019","unstructured":"Lambert M et al (2019) Direct and indirect targeting of HOXA9 transcription factor in acute myeloid leukemia. Cancers (Basel) 17:837\u2013875. https:\/\/doi.org\/10.3390\/cancers11060837","journal-title":"Cancers (Basel)"},{"key":"1561_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/febs.16268","volume":"2","author":"S Aryal","year":"2021","unstructured":"Aryal S, Zhang Y, Wren S, Li C, Lu R (2021) Molecular regulators of HOXA9 in acute myeloid leukemia. FEBS J 2:3\u20139. https:\/\/doi.org\/10.1111\/febs.16268","journal-title":"FEBS J"},{"key":"1561_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/onc.2015.174","volume":"176","author":"CT Collins","year":"2016","unstructured":"Collins CT, Hess JL (2016) Role of HOXA9 in leukemia: dysregulation, cofactors and essential targets. Physiol Behav 176:139\u2013148. https:\/\/doi.org\/10.1038\/onc.2015.174","journal-title":"Physiol Behav"},{"key":"1561_CR14","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/leu.2016.2","volume":"30","author":"Q Cao","year":"2016","unstructured":"Cao Q et al (2016) BCOR regulates myeloid cell proliferation and differentiation Qi. Leukemia 30:1155\u20131165. https:\/\/doi.org\/10.1038\/leu.2016.2","journal-title":"Leukemia"},{"key":"1561_CR15","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a030320","volume":"7","author":"L Brunetti","year":"2017","unstructured":"Brunetti L, Gundry MC, Goodell MA (2017) DNMT3A in leukemia. Cold Spring Harb Perspect Med 7:a030320. https:\/\/doi.org\/10.1101\/cshperspect.a030320","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1561_CR16","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/leu.2011.90","volume":"25","author":"BV Balgobind","year":"2011","unstructured":"Balgobind BV, Zwaan CM, Pieters R, Van Den Heuvel-Eibrink MM (2011) The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Leukemia 25:1239\u20131248. https:\/\/doi.org\/10.1038\/leu.2011.90","journal-title":"Leukemia"},{"key":"1561_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101169","volume":"14","author":"W Zhang","year":"2021","unstructured":"Zhang W, Gou P, Dupret J-M, Chomienne C, Rodrigues-Lima F (2021) Etoposide, an anticancer drug involved in therapy-related secondary leukemia: enzymes at play. Transl Oncol 14:101169. https:\/\/doi.org\/10.1016\/j.tranon.2021.101169","journal-title":"Transl Oncol"},{"key":"1561_CR18","doi-asserted-by":"publisher","first-page":"4461","DOI":"10.1182\/blood-2012-05-429274","volume":"120","author":"A Shi","year":"2012","unstructured":"Shi A et al (2012) Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood 120:4461\u20134469. https:\/\/doi.org\/10.1182\/blood-2012-05-429274","journal-title":"Blood"},{"key":"1561_CR19","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1182\/asheducation-2013.1.596","volume":"1","author":"P Brown","year":"2013","unstructured":"Brown P (2013) Treatment of infant leukemias: challenge and promise. Am Soc Hematol 1:596\u2013600. https:\/\/doi.org\/10.1182\/asheducation-2013.1.596","journal-title":"Am Soc Hematol"},{"key":"1561_CR20","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","volume":"37","author":"C Meyer","year":"2023","unstructured":"Meyer C et al (2023) The KMT2A recombinome of acute leukemias in 2023. Leukemia 37:988\u20131005. https:\/\/doi.org\/10.1038\/s41375-023-01877-1","journal-title":"Leukemia"},{"key":"1561_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/leu.2017.213","volume":"32","author":"C Meyer","year":"2018","unstructured":"Meyer C et al (2018) The MLL recombinome of acute leukemias in 2017. Leukemia 32:273\u2013284. https:\/\/doi.org\/10.1038\/leu.2017.213","journal-title":"Leukemia"},{"key":"1561_CR22","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1038\/leu.2009.33","volume":"23","author":"C Meyer","year":"2009","unstructured":"Meyer C et al (2009) New insights to the MLL recombinome of acute leukemias. Leukemia 23:1490\u20131499. https:\/\/doi.org\/10.1038\/leu.2009.33","journal-title":"Leukemia"},{"key":"1561_CR23","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.3390\/curroncol29090491","volume":"29","author":"RJ Stubbins","year":"2022","unstructured":"Stubbins RJ, Francis A, Kuchenbauer F, Sanford D (2022) Management of acute myeloid leukemia: a review for general practitioners in oncology. Curr Oncol 29:6245\u20136259. https:\/\/doi.org\/10.3390\/curroncol29090491","journal-title":"Curr Oncol"},{"key":"1561_CR24","doi-asserted-by":"publisher","first-page":"7956","DOI":"10.1073\/pnas.1103154108","volume":"108","author":"K Orlovsky","year":"2011","unstructured":"Orlovsky K et al (2011) Down-regulation of homeobox genes MEIS1 and HOXA in MLL -rearranged acute leukemia impairs engraftment and reduces proliferation. Proc Natl Acad Sci U S A 108:7956\u20137961. https:\/\/doi.org\/10.1073\/pnas.1103154108","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1561_CR25","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2007-09-113597","volume":"113","author":"J Faber","year":"2009","unstructured":"Faber J et al (2009) HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 113:2375\u20132385. https:\/\/doi.org\/10.1182\/blood-2007-09-113597","journal-title":"Blood"},{"key":"1561_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.77","volume":"6","author":"M Lambert","year":"2024","unstructured":"Lambert M et al (2024) Induction of AML cell differentiation using HOXA9\/DNA binding inhibitors as a potential therapeutic option for HOXA9-dependent AML. HemaSphere 6:e77. https:\/\/doi.org\/10.1002\/hem3.77","journal-title":"HemaSphere"},{"key":"1561_CR27","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.ccell.2018.08.018","volume":"34","author":"Y Sun","year":"2018","unstructured":"Sun Y et al (2018) HOXA9 reprograms the enhancer landscape to promote leukemogenesis. Cancer Cell 34:643-658.e5. https:\/\/doi.org\/10.1016\/j.ccell.2018.08.018","journal-title":"Cancer Cell"},{"key":"1561_CR28","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1182\/blood-2013-04-497644","volume":"122","author":"SR Daigle","year":"2013","unstructured":"Daigle SR et al (2013) Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 122:1017\u20131025. https:\/\/doi.org\/10.1182\/blood-2013-04-497644","journal-title":"Blood"},{"key":"1561_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ccr.2011.06.009","volume":"20","author":"SR Daigle","year":"2011","unstructured":"Daigle SR et al (2011) Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20:53\u201365. https:\/\/doi.org\/10.1016\/j.ccr.2011.06.009","journal-title":"Cancer Cell"},{"key":"1561_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ccr.2008.05.003","volume":"14","author":"A Yokoyama","year":"2008","unstructured":"Yokoyama A, Cleary ML (2008) Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 14:36\u201346. https:\/\/doi.org\/10.1016\/j.ccr.2008.05.003","journal-title":"Cancer Cell"},{"key":"1561_CR31","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","volume":"123","author":"A Yokoyama","year":"2005","unstructured":"Yokoyama A et al (2005) The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 123:207\u2013218. https:\/\/doi.org\/10.1016\/j.cell.2005.09.025","journal-title":"Cell"},{"key":"1561_CR32","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1182\/blood.2020005037","volume":"136","author":"MM Dzama","year":"2020","unstructured":"Dzama MM et al (2020) Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition. Blood 136:2442\u20132456. https:\/\/doi.org\/10.1182\/blood.2020005037","journal-title":"Blood"},{"key":"1561_CR33","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1182\/blood-2023-189036","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa GC et al (2023) The menin inhibitor revumenib in KMT2A - rearranged or NPM1 -mutant leukaemia. Nature 615:920\u2013924. https:\/\/doi.org\/10.1182\/blood-2023-189036","journal-title":"Nature"},{"key":"1561_CR34","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1021\/ja306028q","volume":"135","author":"H Karatas","year":"2013","unstructured":"Karatas H et al (2013) High-affinity, small-molecule peptidomimetic inhibitors of MLL1\/WDR5 protein\u2013protein interaction. J Am Chem Soc 135:669\u2013682. https:\/\/doi.org\/10.1021\/ja306028q","journal-title":"J Am Chem Soc"},{"key":"1561_CR35","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.cell.2005.03.036","volume":"121","author":"J Wysocka","year":"2005","unstructured":"Wysocka J et al (2005) WDR5 associates with histone H3 methylated at K4 and is essential for H3 K4 methylation and vertebrate development. Cell 121:859\u2013872. https:\/\/doi.org\/10.1016\/j.cell.2005.03.036","journal-title":"Cell"},{"key":"1561_CR36","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/bjh.19508","volume":"205","author":"MWM K\u00fchn","year":"2024","unstructured":"K\u00fchn MWM, Ganser A (2024) The menin story in acute myeloid leukaemia \u2014 the road to success. Br J Haematol 205:812\u2013814. https:\/\/doi.org\/10.1111\/bjh.19508","journal-title":"Br J Haematol"},{"key":"1561_CR37","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1124\/jpet.114.214577","volume":"350","author":"CR Klaus","year":"2014","unstructured":"Klaus CR et al (2014) DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL -rearranged leukemia cells. J Pharmacol Exp Ther 350:646\u2013656. https:\/\/doi.org\/10.1124\/jpet.114.214577","journal-title":"J Pharmacol Exp Ther"},{"key":"1561_CR38","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40487-024-00262-x","volume":"12","author":"X Thomas","year":"2024","unstructured":"Thomas X (2024) Small molecule menin inhibitors: novel therapeutic agents targeting acute myeloid leukemia with KMT2A rearrangement or NPM1 mutation. Oncol Ther 12:57\u201372. https:\/\/doi.org\/10.1007\/s40487-024-00262-x","journal-title":"Oncol Ther"},{"key":"1561_CR39","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.3324\/haematol.2022.282621","volume":"109","author":"MY Salman","year":"2024","unstructured":"Salman MY, Stein EM (2024) Revumenib for patients with acute leukemia\u202f: a new tool for differentiation therapy. Haematologica 109:3488\u20133495. https:\/\/doi.org\/10.3324\/haematol.2022.282621","journal-title":"Haematologica"},{"key":"1561_CR40","doi-asserted-by":"publisher","first-page":"9451","DOI":"10.1007\/s00432-023-04752-9","volume":"149","author":"WCM Dempke","year":"2023","unstructured":"Dempke WCM, Desole M, Chiusolo P, Sica S, Schmidt-Hieber M (2023) Targeting the undruggable: menin inhibitors ante portas. J Cancer Res Clin Oncol 149:9451\u20139459. https:\/\/doi.org\/10.1007\/s00432-023-04752-9","journal-title":"J Cancer Res Clin Oncol"},{"key":"1561_CR41","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","volume":"615","author":"F Perner","year":"2023","unstructured":"Perner F et al (2023) MEN1 mutations mediate clinical resistance to menin inhibition. Nature 615:913\u2013919. https:\/\/doi.org\/10.1038\/s41586-023-05755-9","journal-title":"Nature"},{"key":"1561_CR42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00826","author":"GC Issa","year":"2024","unstructured":"Issa GC, Aldoss I, Thirman MJ, Dipersio J, Arellano M (2024) Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.24.00826","journal-title":"J Clin Oncol"},{"key":"1561_CR43","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1128\/MCB.24.9.3827-3837.2004","volume":"24","author":"U Vijapurkar","year":"2024","unstructured":"Vijapurkar U et al (2024) Protein kinase C-mediated phosphorylation of the leukemia-associated HOXA9 protein impairs its DNA binding ability and induces myeloid differentiation. Mol Cell Biol 24:3827\u20133837. https:\/\/doi.org\/10.1128\/MCB.24.9.3827-3837.2004","journal-title":"Mol Cell Biol"},{"key":"1561_CR44","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.1182\/blood-2011-10-384685","volume":"120","author":"C Breitinger","year":"2012","unstructured":"Breitinger C, Maethner E, Garcia-Cuellar MP, Slany RK (2012) The homeodomain region controls the phenotype of HOX-induced murine leukemia. Blood 120:4018\u20134027. https:\/\/doi.org\/10.1182\/blood-2011-10-384685","journal-title":"Blood"},{"key":"1561_CR45","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1021\/acs.jmedchem.8b01448","volume":"62","author":"S Depauw","year":"2019","unstructured":"Depauw S et al (2019) Heterocyclic diamidine DNA ligands as HOXA9 transcription factor inhibitors: design, molecular evaluation, and cellular consequences in a HOXA9-dependant leukemia cell model. J Med Chem 62:1306\u20131329. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01448","journal-title":"J Med Chem"},{"key":"1561_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.64960","volume":"10","author":"WF Richter","year":"2021","unstructured":"Richter WF, Shah RN, Ruthenburg AJ (2021) Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia. Elife 10:1\u201338. https:\/\/doi.org\/10.7554\/eLife.64960","journal-title":"Elife"},{"key":"1561_CR47","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1158\/1535-7163.MCT-16-0693","volume":"16","author":"CT Campbell","year":"2017","unstructured":"Campbell CT et al (2017) Mechanisms of pinometostat (EPZ-5676) treatment\u2013emergent resistance in MLL-rearranged leukemia. Mol Cancer Ther 16:1669\u20131679. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0693","journal-title":"Mol Cancer Ther"},{"key":"1561_CR48","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1158\/2159-8290.CD-16-0237","volume":"6","author":"MWM K\u00fchn","year":"2016","unstructured":"K\u00fchn MWM et al (2016) Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia. Cancer Discov 6:1166\u20131181. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0237","journal-title":"Cancer Discov"},{"key":"1561_CR49","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1084\/jem.20052242","volume":"203","author":"HS Radomska","year":"2006","unstructured":"Radomska HS et al (2006) Block of C\/EBP\u03b1 function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J Exp Med 203:371\u2013381. https:\/\/doi.org\/10.1084\/jem.20052242","journal-title":"J Exp Med"},{"issue":"41","key":"1561_CR50","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.21873\/anticanres.14950","volume":"2","author":"Y Sonoda","year":"2021","unstructured":"Sonoda Y, Itoh M, Tohda S (2021) Effects of HOXA9 inhibitor DB818 on the growth of acute myeloid leukaemia cells. Anticancer Res 2(41):1841\u20131847. https:\/\/doi.org\/10.21873\/anticanres.14950","journal-title":"Anticancer Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01561-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01561-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01561-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:03:26Z","timestamp":1760195006000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01561-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1561"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01561-4","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}